Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer
2007
Colorectal cancer statistics, 2014
2014 Standout
Colorectal cancer statistics, 2023
2023 Standout
Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study
2011
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
2012
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Letrozole in the extended adjuvant setting: MA.17
2007
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer
2011
Estrogen Receptors: How Do They Signal and What Are Their Targets
2007 Standout
Breast cancer
2016 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Nutrition and physical activity guidelines for cancer survivors
2012 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
2010 Standout
A woman's heart
2009
Colorectal cancer
2019 Standout
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
2010
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
2013
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
2004 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
1989 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
2009
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates
2009 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Light‐Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy
2015 StandoutNobel
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Stage II malignant melanoma: Presentation of a prognostic model and an assessment of specific active immunotherapy in 1,273 patients
1988
Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
2011
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma
2007
Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable
2019 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Does tumour dormancy offer a therapeutic target?
2010
Late Recurrences in Early Breast Cancer: For Whom and How Long Is Endocrine Therapy Beneficial?
2014
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
2011
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Clinical Management of Oxaliplatin-Associated Neurotoxicity
2005
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
2009 Standout
Preventing Relapse Beyond 5 Years: The MA.17 Extended Adjuvant Trial
2006
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
2007
First international consensus guidelines for breast cancer in young women (BCY1)
2014
Preservation of Fertility in Patients with Cancer
2009 Standout
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
2005
Triple-negative breast cancer—current status and future directions
2009
Acral with melanoma: A review of 185 patients identification of prognostic variables
1990
Lethal “Thin” Malignant Melanoma
1988
Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development
2021 StandoutNobel
Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089
2005
Cutaneous Adverse Effects With HER1/EGFR-Targeted Agents: Is There a Silver Lining?
2005
Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study
2011
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
2009 Standout
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
2001 Standout
Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group
2006
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
2010
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Malignant melanoma patients with positive nodes and relatively good prognoses: Microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes
1981
Diabetes and Cancer
2010 Standout
Decision aids for people facing health treatment or screening decisions
2017 Standout
Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover
2011
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
2017 Standout
Colorectal cancer statistics, 2017
2017 Standout
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
2005
Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy
2011
How I treat acute promyelocytic leukemia
2009
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
2001 Standout
Histone Deacetylase Inhibitors in Cancer Therapy
2009
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer
2006
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
2010
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
2007
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Prognostic Role of Vitamin D Status and Efficacy of Vitamin D Supplementation in Cancer Patients: A Systematic Review
2011
Works of L. E. Shepherd being referenced
A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer
2005
Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
2003
Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer
2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17
2008
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole
2012
NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months
2006
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials
2004
Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5)
2006
Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial
2009
NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer
2008
Duplication of Chromosome 17 CEP Predicts for Anthracycline Benefit: A Meta-Analysis of 4 Trials.
2009
Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer
2004
The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial.
2011
Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer
2004
Microgranular Variant (M3V) of Acute Promyelocytic Leukemia (APL) Does Not Have a Worse Prognosis than Classical APL in the Atra Era: A Report of 153 Patients Treated on Intergroup 0129 and Pethema LPA96 and LPA99.
2004
Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials
2004
Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial
2008
Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16
2007
Specific Active Immunotherapy for Melanoma
1979
Predicting survival with health-related quality of life scores in locally advanced breast cancer: Results from an international randomized controlled trial
2004